Cargando…

Targeting immune checkpoints in malignant glioma

Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuhao, Zhu, Shan, Li, Tete, Liu, Yong-Jun, Chen, Wei, Chen, Jingtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351697/
https://www.ncbi.nlm.nih.gov/pubmed/27756892
http://dx.doi.org/10.18632/oncotarget.12702
_version_ 1782514816741539840
author Zhang, Xuhao
Zhu, Shan
Li, Tete
Liu, Yong-Jun
Chen, Wei
Chen, Jingtao
author_facet Zhang, Xuhao
Zhu, Shan
Li, Tete
Liu, Yong-Jun
Chen, Wei
Chen, Jingtao
author_sort Zhang, Xuhao
collection PubMed
description Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors. Although once considered immune privileged and devoid of normal immunological functions, CNS is now considered a promising target for cancer immunotherapy, featuring the recent progresses in neurobiology and neuroimmunology and a highly immunosuppressive state in malignant glioma. In this review, we focus on immune checkpoint inhibitors, specifically, antagonizing monoclonal antibodies for programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and indoleamine 2,3-dioxygenase (IDO). We discuss advances in the working mechanisms of these immune checkpoint molecules, their status in malignant glioma, and current preclinical and clinical trials targeting these molecules in malignant glioma.
format Online
Article
Text
id pubmed-5351697
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53516972017-04-13 Targeting immune checkpoints in malignant glioma Zhang, Xuhao Zhu, Shan Li, Tete Liu, Yong-Jun Chen, Wei Chen, Jingtao Oncotarget Review Malignant glioma is the most common and a highly aggressive cancer in the central nervous system (CNS). Cancer immunotherapy, strategies to boost the bodys anti-cancer immune responses instead of directly targeting tumor cells, recently achieved great success in treating several human solid tumors. Although once considered immune privileged and devoid of normal immunological functions, CNS is now considered a promising target for cancer immunotherapy, featuring the recent progresses in neurobiology and neuroimmunology and a highly immunosuppressive state in malignant glioma. In this review, we focus on immune checkpoint inhibitors, specifically, antagonizing monoclonal antibodies for programmed cell death protein-1 (PD-1), cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), and indoleamine 2,3-dioxygenase (IDO). We discuss advances in the working mechanisms of these immune checkpoint molecules, their status in malignant glioma, and current preclinical and clinical trials targeting these molecules in malignant glioma. Impact Journals LLC 2016-10-16 /pmc/articles/PMC5351697/ /pubmed/27756892 http://dx.doi.org/10.18632/oncotarget.12702 Text en Copyright: © 2017 Zhang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Zhang, Xuhao
Zhu, Shan
Li, Tete
Liu, Yong-Jun
Chen, Wei
Chen, Jingtao
Targeting immune checkpoints in malignant glioma
title Targeting immune checkpoints in malignant glioma
title_full Targeting immune checkpoints in malignant glioma
title_fullStr Targeting immune checkpoints in malignant glioma
title_full_unstemmed Targeting immune checkpoints in malignant glioma
title_short Targeting immune checkpoints in malignant glioma
title_sort targeting immune checkpoints in malignant glioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351697/
https://www.ncbi.nlm.nih.gov/pubmed/27756892
http://dx.doi.org/10.18632/oncotarget.12702
work_keys_str_mv AT zhangxuhao targetingimmunecheckpointsinmalignantglioma
AT zhushan targetingimmunecheckpointsinmalignantglioma
AT litete targetingimmunecheckpointsinmalignantglioma
AT liuyongjun targetingimmunecheckpointsinmalignantglioma
AT chenwei targetingimmunecheckpointsinmalignantglioma
AT chenjingtao targetingimmunecheckpointsinmalignantglioma